| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/13/2023 | 862.03% | Cantor Fitzgerald | → $38 | Reiterates | Overweight → Overweight |
| 05/24/2023 | 406.33% | Alliance Global Partners | → $20 | Reiterates | → Buy |
| 11/14/2022 | 51.9% | SVB Leerink | $5 → $6 | Maintains | Market Perform |
| 11/08/2022 | 912.66% | Cantor Fitzgerald | $22 → $40 | Maintains | Overweight |
| 08/11/2022 | 26.58% | SVB Leerink | $1 → $5 | Maintains | Market Perform |
| 11/30/2021 | -74.68% | SVB Leerink | $5 → $1 | Downgrades | Outperform → Market Perform |
| 11/29/2021 | 1.27% | HC Wainwright & Co. | $5 → $4 | Maintains | Buy |
| 07/19/2021 | 26.58% | HC Wainwright & Co. | $8 → $5 | Maintains | Buy |
| 11/25/2020 | 102.53% | HC Wainwright & Co. | $11 → $8 | Maintains | Buy |
| 11/11/2020 | 1.27% | Cantor Fitzgerald | → $4 | Upgrades | Neutral → Overweight |
| 11/10/2020 | 26.58% | SVB Leerink | $8 → $5 | Maintains | Outperform |
| 09/18/2020 | 26.58% | B. Riley Securities | → $5 | Initiates Coverage On | → Buy |
| 05/08/2020 | 77.22% | RBC Capital | $11 → $7 | Maintains | Outperform |
| 03/18/2020 | 178.48% | RBC Capital | $14 → $11 | Maintains | Outperform |
| 02/10/2020 | 51.9% | SVB Leerink | → $6 | Maintains | Outperform |
| 12/30/2019 | 178.48% | HC Wainwright & Co. | $15 → $11 | Reiterates | → Buy |
| 08/15/2019 | — | Maxim Group | Downgrades | Buy → Hold | |
| 08/12/2019 | -49.37% | Cantor Fitzgerald | $29 → $2 | Downgrades | Overweight → Neutral |
| 08/12/2019 | 279.75% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 07/26/2019 | — | Mizuho | Downgrades | Buy → Neutral | |
| 11/13/2018 | 608.86% | Citigroup | $32 → $28 | Maintains | Buy |
What is the target price for Abeona Therapeutics (ABEO)?
The latest price target for Abeona Therapeutics (NASDAQ: ABEO) was reported by Cantor Fitzgerald on July 13, 2023. The analyst firm set a price target for $38.00 expecting ABEO to rise to within 12 months (a possible 862.03% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Abeona Therapeutics (ABEO)?
The latest analyst rating for Abeona Therapeutics (NASDAQ: ABEO) was provided by Cantor Fitzgerald, and Abeona Therapeutics reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Abeona Therapeutics (ABEO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abeona Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abeona Therapeutics was filed on July 13, 2023 so you should expect the next rating to be made available sometime around July 13, 2024.
Is the Analyst Rating Abeona Therapeutics (ABEO) correct?
While ratings are subjective and will change, the latest Abeona Therapeutics (ABEO) rating was a reiterated with a price target of $0.00 to $38.00. The current price Abeona Therapeutics (ABEO) is trading at is $3.95, which is within the analyst's predicted range.